This brand name is authorized in United States. It is also authorized in Australia, Canada, South Africa.
The drug RIDAURA contains one active pharmaceutical ingredient (API):
1
|
UNII
3H04W2810V - AURANOFIN
|
|
Auranofin is an orally available compound, used to treat rheumatoid arthritis, with anti-inflammatory activities. The main mechanism of action of auranofin is through the inhibition of reduction/oxidation (redox) enzymes such as thioredoxin reductase (TrxR). The thiol ligand contained in auranofin has a high affinity for thiol and selenol groups, to which it forms stable, and irreversible, adducts. Redox enzymes such as TrxR are essential to many cellular processes, particularly in maintaining the intracellular levels of reactive oxygen species (ROS). |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| M01CB03 | Auranofin | M Musculo-skeletal system → M01 Antiinflammatory and antirheumatic products → M01C Specific antirheumatic agents → M01CB Gold preparations |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| AU | Pharmaceutical Benefits Scheme | 1095P, 2022K |
| CA | Health Products and Food Branch | 01916823 |
| US | FDA, National Drug Code | 54766-093 |
| ZA | Health Products Regulatory Authority | P/3.1/0250 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.